Close

Piper Jaffray Cuts PT on Alnylam (ALNY) by 45%; Keep 'Overweight'

February 12, 2016 8:26 AM EST Send to a Friend
Piper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login